Rasna Therapeutics

Rasna Therapeutics, Inc. is a development-stage biotechnology company primarily focused on developing drug candidates for leukemia and lymphoma. Aberrant epigenetic modifications are believed to play a significant role in the pathogenesis of acute myeloid leukemia (AML), leading to the silencing of genes involved in tumor suppression and cell proliferation. Rasna focuses on inhibiting lysine-specific demethylase 1 (LSD1), an enzyme involved in epigenetic control, representing a promising novel approach for AML. Rasna has developed new irreversible and reversible LSD1 modulators, demonstrating appropriate effects on the LSD1 gene in in vitro and IND-enabling preclinical studies.